Jennifer Kozak is Vice President, Business Development in Johnson & Johnson’s Medical Devices group.   In this role, Jennifer is responsible for Business Development (BD) activities for New Growth Platforms.  She also works to develop and lead new external innovation models and works with Johnson & Johnson Development Corporation to optimize our equity investment strategy and portfolio.  Jennifer has led numerous BD projects and strategic assessments, including the strategy to enter the ENT (Ears, Nose, Throat) space leading to the acquisition of Acclarent, and the Angiotech knotless tissue closure device asset acquisition.  She began her career at Johnson & Johnson as an engineer at Johnson & Johnson Interventional Systems prior to the merger with Cordis Corporation.  While at Cordis, she held various roles in Operations, R&D and New Business Development.  Following Cordis, she joined Ethicon, Inc. a Johnson & Johnson company in New Business Development responsible for New Growth Opportunities.  Jennifer has a BS in Chemical Engineering from Bucknell University, and completed the Smith College Leadership Consortium Executive Education.